AI assistant
Private Equity Holding AG — Interim / Quarterly Report 2021
Nov 4, 2021
958_10-q_2021-11-04_24ef43f1-0b50-4ce8-bc52-705343df8320.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Half-Year Report as of September 30, 2021
Private Equity Holding AG
Private Equity Holding offers institutional and private investors the opportunity to invest in a broadly diversified private equity portfolio.
The objective of Private Equity Holding is to generate long term capital growth for its shareholders.
Private Equity Holding's Investment Portfolio is managed by Alpha Associates.
Alpha Associates is an independent private equity, private debt and infrastructure manager and advisor, building and managing globally diversified private market fund portfolios for institutional and private clients.
Table of Contents
| Key Figures 2 |
|---|
| Chairman's Letter for the First Half of the Financial Year 2021/2022 3 |
| Development of Net Asset Value and Share Price 5 |
| Portfolio Overview 6 |
| Statement of Comprehensive Income 10 |
| Balance Sheet 11 |
| Statement of Changes in Equity 12 |
| Statement of Cash Flows 13 |
| Notes to the Financial Statements 14 |
| Information for Investors 24 |
| Glossary of Terms 25 |
Key Figures for the First Half of the Financial Year 2021/2022
| Share Value | 30.09.21 EUR |
31.03.21 EUR |
Change in %1 |
30.09.21 CHF |
31.03.21 CHF |
Change in %1 |
|---|---|---|---|---|---|---|
| Net asset value per share, based on fair values | 141.50 | 121.33 | 16.6% | 152.99 | 134.20 | 14.0% |
| Price per share (PEHN.S) | 83.24 | 66.90 | 24.4% | 90.00 | 74.00 | 21.6% |
1 Excl. distributions.
| Net Profit/(Loss) for the Period | 01.04.21- 30.09.21 EUR 1,000 |
01.04.20- 30.09.20 EUR 1,000 |
Change in % |
|---|---|---|---|
| Profit/(loss) for the period | 55,178 | (12,193) | n/a |
| Selected Balance Sheet Items (Consolidated)2 | 30.09.21 EUR 1,000 |
31.03.21 EUR 1,000 |
Change in % |
|---|---|---|---|
| Current assets | 3,537 | 4,664 | (24%) |
| Non-current assets | 364,116 | 316,557 | 15% |
| Current liabilities | 9,924 | 13,152 | (25%) |
| Non-current liabilities | — | — | n/a |
| Total equity | 357,729 | 308,069 | 16% |
2 Information herein is presented in addition to the IFRS Interim Financial Statements.
| Asset Allocation | Fair Value 30.09.21 EUR million |
Unfunded Commitments 30.09.21 EUR million |
Total Exposure3 30.09.21 EUR million |
Total Exposure3 30.09.21 in % |
|---|---|---|---|---|
| Buyout funds | 116.2 | 56.4 | 172.6 | 36% |
| Venture funds | 112.0 | 24.9 | 136.9 | 29% |
| Special situation funds | 58.8 | 28.5 | 87.3 | 18% |
| Total fund investments | 287.0 | 109.8 | 396.8 | 83% |
| Direct investments and loans | 77.1 | 6.4 | 83.5 | 17% |
| Total direct investments and loans | 77.1 | 6.4 | 83.5 | 17% |
| Total funds, direct investments and loans | 364.1 | 116.2 | 480.3 | 100% |
3 Fair value plus unfunded commitments.
| Commitments | 30.09.21 | 31.03.21 | Change in % |
|---|---|---|---|
| Unfunded commitments (EUR million) | 116.2 | 80.8 | 44% |
| Overcommitment4 | 32.4% | 26.8% | 21% |
| Net current assets / unfunded commitments | 0.2% | (3.2%) | n/a |
4 Overcommitment = (unfunded commitments - net current assets) / (non-current assets - non-current liabilities).
n/a = not meaningful
Chairman's Letter for the First Half of the Financial Year 2021/2022
Dear Shareholders,
As of September 30, 2021, PEH reports a comprehensive income of EUR 55.2m and a net asset value per share (NAV) of EUR 141.50 (CHF 152.99), representing an increase of +18.1% in EUR (+15.5% in CHF) over the course of the reporting period and including the distribution of CHF 2.00 per share in June 2021. This marks an exceptional performance and lifts the total equity of the company above EUR 350m.
Strong Portfolio Performance
The NAV development was positive in five of the six months of the half-year reporting period, resulting in substantial NAV growth of 71.8% in EUR (+72.5% in CHF) year on year. The portfolio benefited from its sector exposure to technology and healthcare, several landmark IPOs and strong valuation gains based on market sentiment but also strong fundamentals. This held true for the fund portfolio in general, and also for several direct co-investments, incl. Earnix, an Israeli artificial intelligence software provider, Ozon.ru, a Russian online retailer, Dupont Sustainable Solutions, a leader in health, safety and environmental consulting, and Renaissance Learning, a digital learning solutions provider.
PEH received EUR 46.6m in distributions in the reporting period. One of the largest distributions came from Capvis III from a secondary transaction of the remaining assets in the fund; other noteworthy distributions were received from (i) ABRY VIII from the sale of Donuts, a domain name registry company, (ii) Avista IV distributing shares in kind of Organogenesis Holdings, a leading regenerative medicine company, as well as from (iii) Highland Europe II distributing proceeds from the sale of Condeco, a leading provider of integrated workspace booking solutions.
Increased Investment Activity
Due to uncertainties surrounding the impact of the COVID-19 pandemic and the aim of reducing PEH's credit facility usage, the investment activity in the financial year 2020/21 was somewhat muted. With the credit facility usage having been minimised at calendar year end, the overall positive market sentiment and very strong portfolio NAV development, has allowed for a more active investment activity throughout the first half of the financial year 2021/22.
PEH successfully completed several new investments in the first half of the financial year; these include a USD 7.0m commitment to TA XIV, a fund targeting growth capital investments in the middle market in the US and Europe as well as a USD 6.0m commitment to Abry Senior Equity VI, a fund completing senior equity investments in the media, communications, information and business services sectors in North America. Both fund managers are existing relationships for PEH.
Other new investments include a EUR 4.5m commitment to funds managed by Gyrus Capital, continuing a highly successful investment relationship following the co-investment in Dupont Sustainable Solutions, an operations management consulting firm, a USD 2.0m commitment to Insight Partners XII Buyout Annex Fund, a US-based growth equity fund focusing on the SaaS Market and a GBP 9.0m commitment to Pollen Street Capital IV, a lower mid-market fund focusing on financial and business services' companies in the UK.
Moreover, EUR 4.4m were invested via a single asset secondary transaction in Regina Maria, a private healthcare platform in Romania and Serbia.
Strategic Outlook
The Board of Directors continues to follow a three-fold strategy of committing to select investments for long-term growth, NAV accretion via treasury share transactions and providing investors with regular yield. After a reduced dividend in 2020 the Board of Directors decided to increase the dividend again and CHF 2.00 per share were paid to shareholders in June. The investment part of the strategy will continue to be overweight to lay the foundation allowing for future strategic continuity in also making significant distributions to shareholders in the form of NAV accretion and dividend payments.
We have highlighted both here and in many dialogues with shareholders that we continue to consider the discount between NAV and share price too wide and not reflecting PEH's fundamental characteristics and the inherent quality of the portfolio. Matter-of-factly, even the share price increase of more than 20% in the reporting period has not led to a narrowing of the discount given the strong NAV performance.
We remain convinced of the high quality of the portfolio and the resulting future perspective for PEH. Hence, members of both the Board of Directors and the Manager have purchased PEH shares for more than CHF 6m during the reporting period, underlining the strong commitment to and conviction of PEH.
Congratulations to Swissloop Tunneling
Lastly, we would like to take the opportunity to present a project that is close to our hearts: Swissloop Tunneling (www.swisslooptunneling.ch), the official student team of ETH Zurich, comprising of 40 students with expertise in mechanical and electrical engineering. The project has a vision to spearhead the research on infrastructure by developing an innovative tunneling robot that would allow the (Hyper)loop concept to become reality. PEH is proud to support the Swissloop Tunneling project as a gold partner and congratulates the team for placing 2nd in Elon Musk's Not-A-Boring-Competition in Las Vegas in September 2021 and winning the Innovation and Design category.
In the name of the entire Board of Directors and the Manager, I would like to thank you for your continued support and interest in PEH.
Dr. Hans Baumgartner Chairman of the Board of Directors November 4, 2021
Development of Net Asset Value and Share Price
Share Price and NAV per Share 01.01.2007 - 30.09.2021 (incl. distributions)
Relative Performance of PEHN 01.01.2007 - 30.09.2021 (incl. distributions)
PEHN has outperformed the LPX-50 PE-Index by: 156.0%
PEHN has outperformed the MSCI World Index by: 93.0%
Portfolio Overview
Allocation by Investment Category1 Fair Value by Vintage Year
1 Based on fair values plus unfunded commitments of portfolio holdings
2 Based on fair values of the underlying companies
Allocation by Geography2 Unfunded Commitments by Vintage Year
Allocation by Industry2 10 Largest Exposures by Manager
Five Largest Exposures by Fair Value*
representing 25.0% of the total fair value of PEH's investment portfolio
Alpha CEE Opportunity IV
Type: Buyout Industries: Various
Fund Size: EUR 144 million Region: Central & Eastern Europe Fair Value: EUR 25.1 million 6.9% of PEH Portfolio
Growth Fund II
| Fund Size: | EUR 509 million |
|---|---|
| Type: | Venture/Growth |
| Industries: | Various |
| Region: | Europe |
| Fair Value: | EUR 22.8 million 6.3% of PEH Portfolio |
Earnix
| Type: | Direct Co-Investment |
|---|---|
| Industries: | IT/Software |
| Region: | Israel |
| Fair Value: | EUR 15.2 million 4.2% of PEH Portfolio |
Mid Europa Fund IV
| Fund Size: | EUR 808 million |
|---|---|
| Type: | Buyout |
| Industries: | Various |
| Region: | Central & Eastern Europe |
| Fair Value: | EUR 14.2 million 3.9% of PEH Portfolio |
Pollen Street III
- Fund Size: GBP 348 million Type: Buyout Industries: Financials Region: Europe
- Fair Value: EUR 13.6 million 3.7% of PEH Portfolio
Five Largest Exposures by Unfunded Commitment*
representing 30.6% of the total unfunded commitments of PEH's investment portfolio
Pollen Street IV
Fund Size: GBP 497 million Type: Buyout Industries: Financials Region: Europe Unfunded Commitment: EUR 10.5 million
| 9.0% of PEH Portfolio |
|---|
Abry Heritage Partners II
| Fund Size: | n/a |
|---|---|
| Type: | Buyout |
| Industries: | IT/Software |
| Region: | North America |
| Unfunded Commitment: | EUR 8.6 million 7.4% of PEH Portfolio |
TA Associates XIV
| Fund Size: | USD 12.5 billion |
|---|---|
| Type: | Buyout |
| Industries: | Various |
| Region: | North America |
| Unfunded Commitment: | EUR 6.0 million 5.2% of PEH Portfolio |
Abry Senior Equity VI
| Fund Size: | n/a |
|---|---|
| Type: | Special Situation |
| Industries: | Media/Communications |
| Region: | North America |
| Unfunded Commitment: | EUR 5.2 million 4.5% of PEH Portfolio |
Growth Fund V
Fund Size: USD 2.0 billion Type: Venture/Growth Industries: Various Region: Europe Unfunded Commitment: EUR 5.2 million
4.5% of PEH Portfolio
* Expressed in EUR, by the Company's functional currency
Statement of Comprehensive Income
| EUR 1,000 | Notes | 01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
|---|---|---|---|
| Income | |||
| Net gains from investments in non-consolidated subsidiaries at fair value through profit or loss | 11 | 56,889 | (10,888) |
| Net gains/(losses) from financial assets at fair value through profit or loss | 11 | — | (543) |
| Foreign exchange gains/(losses) | (643) | 223 | |
| Interest income calculated using effective interest rate method | — | 17 | |
| Total income | 56,246 | (11,191) | |
| Expenses | |||
| Administration expenses | 5 | 230 | 234 |
| Corporate expenses | 6 | 411 | 359 |
| Total expenses | 641 | 593 | |
| Profit/(loss) from operations | 55,605 | (11,784) | |
| Interest expenses | (427) | (409) | |
| Profit/(loss) for the period attributable to equity holders of the company | 55,178 | (12,193) | |
| Other comprehensive income | |||
| Other comprehensive income for the period, net of income tax | — | — | |
| Total comprehensive income/(loss) for the period attributable to equity holders of the company | 55,178 | (12,193) | |
| 01.04.21- | 01.04.20- |
| 30.09.21 | 30.09.20 | |
|---|---|---|
| Weighted average number of shares outstanding during period | 2,535,363 | 2,587,994 |
| Basic earnings per share (EUR) | 21.76 | (4.71) |
Minor differences in totals are due to rounding.
Balance Sheet
| EUR 1,000 | Notes | 30.09.21 | 31.03.21 |
|---|---|---|---|
| Assets | |||
| Current assets | |||
| Cash and cash equivalents | 131 | 218 | |
| Receivables and prepayments | 203 | 112 | |
| Total current assets | 334 | 330 | |
| Non-current assets | |||
| Investments in non-consolidated subsidiaries at fair value through profit or loss | 10 | 423,936 | 367,047 |
| Financial assets at fair value through profit or loss | 10 | 1,285 | 1,285 |
| Total non-current assets | 425,221 | 368,332 | |
| Total assets | 425,555 | 368,662 | |
| Liabilities and equity | |||
| Current liabilities | |||
| Payables and other accrued expenses | 7 | 320 | 93 |
| Short-term bank borrowings | 9 | 6,600 | 5,878 |
| Total current liabilities | 6,920 | 5,971 | |
| Non-current liabilities | |||
| Interest bearing borrowings | 9 | 60,906 | 54,622 |
| Total non-current liabilities | 60,906 | 54,622 | |
| Total liabilities | 67,826 | 60,593 | |
| Equity | |||
| Share capital | 10,311 | 10,311 | |
| Share premium | 24,599 | 26,156 | |
| Treasury shares | (13,249) | (12,358) | |
| Retained earnings | 336,068 | 283,960 | |
| Total equity | 357,729 | 308,069 | |
| Total liabilities and equity | 425,555 | 368,662 |
| 30.09.21 | 31.03.21 | |
|---|---|---|
| Total number of shares as of period end | 2,750,000 | 2,750,000 |
| Number of treasury shares as of period end | (221,932) | (210,872) |
| Number of shares outstanding as of period end | 2,528,068 | 2,539,128 |
| Net asset value per share (EUR) | 141.50 | 121.33 |
Minor differences in totals are due to rounding.
Statement of Changes in Equity
| EUR 1,000 | Share capital |
Share premium |
Treasury shares |
Retained earnings |
Total equity |
|---|---|---|---|---|---|
| Opening as of 01.04.20 | 10,311 | 26,995 | (9,448) | 202,808 | 230,666 |
| Profit/(loss) for the period | — | — | — | (12,193) | (12,193) |
| Total other comprehensive income for the period, net of income tax | — | — | — | — | — |
| Total comprehensive income/(loss) for the period | — | — | (12,193) | (12,193) | |
| Purchase of treasury shares | — | — | (503) | — | (503) |
| Sale of treasury shares | — | (30) | 146 | — | 116 |
| Distribution to shareholders 1 | — | (809) | — | (1,628) | (2,437) |
| Total contributions by and distributions to owners of the Company | — | (839) | (357) | (1,628) | (2,824) |
| Total as of 30.09.20 | 10,311 | 26,156 | (9,805) | 188,987 | 215,649 |
| Opening as of 01.10.20 | 10,311 | 26,156 | (9,805) | 188,987 | 215,649 |
|---|---|---|---|---|---|
| Profit/(loss) for the period | — | — | — | 94,973 | 94,973 |
| Total other comprehensive income for the period, net of income tax | — | — | — | — | — |
| Total comprehensive income/(loss) for the period | — | — | — | 94,973 | 94,973 |
| Purchase of treasury shares | — | — | (2,553) | — | (2,553) |
| Sale of treasury shares | — | — | — | — | — |
| Distribution to shareholders 1 | — | — | — | — | — |
| Total contributions by and distributions to owners of the Company | — | — | (2,553) | — | (2,553) |
| Total as of 31.03.21 | 10,311 | 26,156 | (12,358) | 283,960 | 308,069 |
| Opening as of 01.04.21 | 10,311 | 26,156 | (12,358) | 283,960 | 308,069 |
|---|---|---|---|---|---|
| Profit/(loss) for the period | — | — | — | 55,178 | 55,178 |
| Total other comprehensive income for the period, net of income tax | — | — | — | — | — |
| Total comprehensive income/(loss) for the period | — | — | — | 55,178 | 55,178 |
| Purchase of treasury shares | — | — | (979) | — | (979) |
| Sale of treasury shares | — | 28 | 88 | — | 116 |
| Distribution to shareholders 2 | — | (1,585) | — | (3,070) | (4,655) |
| Total contributions by and distributions to owners of the Company | — | (1,557) | (891) | (3,070) | (5,518) |
| Total as of 30.09.21 | 10,311 | 24,599 | (13,249) | 336,068 | 357,729 |
Minor differences in totals are due to rounding.
1 The Annual General Meeting held on July 2, 2020 decided on a distribution to shareholders in the amount of CHF 1.00 per outstanding share, which was paid from share premium and from retained earnings. No distribution was made on treasury shares. The distribution was made with value date July 8, 2020.
2The Annual General Meeting held on June 2, 2021 decided on a distribution to shareholders in the amount of CHF 2.00 per outstanding share, which was paid from share premium and from retained earnings. No distribution was made on treasury shares. The distribution was made with value date June 10, 2021.
Statement of Cash Flows
| 01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
|
|---|---|---|
| Cash flow from operating activities | ||
| Interest bearing loans | — | 1,810 |
| Interest received on interest bearing loans | — | 17 |
| Administration expenses paid | (230) | (234) |
| Corporate expenses paid | (279) | (276) |
| Transaction expenses paid | (4) | (4) |
| Net adjustment for other assets and liabilities | (105) | (133) |
| Net cash (used)/provided by operating activities | (618) | 1,180 |
| Cash flow from financing activities | ||
| Proceeds/(Repayments) from interest bearing borrowings | 5,682 | 5,438 |
| Proceeds/(Repayments) from short-term bank borrowings | 674 | (3,115) |
| Interest paid on interest bearing borrowings | (409) | (295) |
| Interest paid on short-term bank borrowings | (18) | (114) |
| Commitment fee on borrowings | (128) | (80) |
| Purchase of treasury shares | (743) | (528) |
| Sale of treasury shares | 116 | 116 |
| Distribution to shareholders | (4,655) | (2,437) |
| Net cash (used)/provided by financing activities | 519 | (1,015) |
| Net increase/(decrease) in cash and cash equivalents | (99) | 165 |
| Cash and cash equivalents at the beginning of the period | 218 | 20 |
| Effects of exchange rate changes on cash and cash equivalents | 12 | 3 |
| Cash and cash equivalents at the end of the period | 131 | 188 |
Minor differences in totals are due to rounding.
Notes to the Financial Statements
1. Reporting entity
Private Equity Holding AG (the "Company") is a stock company incorporated under Swiss law with registered address at Gotthardstrasse 28, 6302 Zug, Switzerland. The business activity of the Company is mainly conducted through investing the Company's assets directly and indirectly through its Cayman Islands non-consolidated subsidiaries (together referred to as the "Group").
The Company controls 100% of the voting rights and ownership interests in Private Equity Fund Finance Ltd and Private Equity Direct Finance Ltd (the "Subsidiaries"). The non-consolidated Subsidiaries are incorporated in the Cayman Islands.
The business activity of the Company is the purchase, holding and disposal of investments held in private equity funds and directly in companies with above-average growth potential. The Board of Directors has appointed one of its members as the Board's Delegate (the "Delegate"), who is responsible for managing the day-to-day business of the Company. ALPHA Associates (Cayman) LP, Cayman Islands, and ALPHA Associates AG, Zurich (together "ALPHA Group" or the "Investment Manager"), act as investment manager and investment adviser, respectively and provide certain support services to the Company.
2. Basis of preparation
a) Statement of compliance
These condensed interim financial statements of the Company have been prepared in accordance with International Accounting Standards (IAS) 34 "Interim Financial Reporting" and do not include all of the information required for full annual financial statements.
These condensed interim financial statements were authorised by the Board of Directors for issue on November 4, 2021.
b) Estimates
The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.
In preparing these condensed interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements as at and for the year ended March 31, 2021.
3. Significant accounting policies
The accounting and valuation principles applied in these interim financial statements correspond to those of the financial statements as at and for the year ended March 31, 2021, unless otherwise stated.
New standards and interpretations
The following new standards, amendments to standards and interpretations are effective for annual periods beginning on or after January 1, 2021.
- Interest Rate Benchmark Reform Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16). For the Financial Instruments, the change in the basis for determining the contractual cash flows is required if (i) it is a direct consequence of the reform, and (ii) the new basis is economically equivalent to the former basis. If the modification does not result in a de-recognition but result in a gain or loss from the reassessment of carrying value, modification gain or loss is to be recognised in profit or loss. Consequently, there is a requirement to make additional disclosure in the financial statements about the process itself and the transition, the nature and the extent of the risks connected to the change in the benchmark rate and how the Partnership manages. The amendments are applied for annual periods beginning on or after January 1, 2021 with earlier application permitted.
- Amendment to IFRS 16 COVID-19 Related Rent Concessions beyond 30 June 2021. Extends the previous amendment that permits lessees, as a practical expedient, not to assess whether particular rent concessions occurring as a direct consequence of the COVID-19 pandemic are lease modifications and instead to account for those rent concessions as if they are not lease modifications. The amendments are applied for annual periods beginning on or after April 1, 2021.
There are no other standards, amendments to standards or interpretations that are effective for annual periods beginning on January 1, 2021 that have a material effect on the condensed interim financial statements of the Company.
New standards, amendments and interpretations that are not yet effective and might be relevant for the Company
In connection with a derecognition resulting from modifications and restructuring of financial liabilities, amendment IFRS 9 – Financial Instruments clarifies which fees to include when applying the '10 percent' test when assessing whether to derecognise a financial liability. Amendment applies for annual periods beginning on or after January 1, 2022 with possible early adoption.
Of those standards and interpretations not yet effective, no others are expected to have a significant impact on the Company's condensed interim financial statement in the period of initial application.
4. Treasury share transactions
The Company held 221,932 treasury shares as of September 30, 2021 (September 30, 2020: 165,158; March 31, 2021: 210,872). The Company has the right to re-issue/sell the treasury shares at any time.
5. Administration expenses
Management and Administration fees as well as Performance fees paid by the Company and its non-consolidated subsidiaries are as follows:
| Non-consolidated PEH Subsidiaries |
Total | ||||||
|---|---|---|---|---|---|---|---|
| EUR 1,000 | 01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
|
| Management and administration fees | 230 | 234 | 2,599 | 1,652 | 2,829 | 1,886 | |
| Performance fees | — | — | 6,131 | — | 6,131 | — | |
| Total | 230 | 234 | 8,730 | 1,652 | 8,960 | 1,886 |
Management and performance fees are paid to ALPHA Associates (Cayman), L.P. a related party. As of September 30, 2021, total management and administration fees and performance fees payable by the Company and non-consolidated subsidiaries amounted to EUR 3.0 million (March 31, 2021: EUR 7.2 million).
Administration fees are paid to ALPHA Associates AG, a related party.
6. Corporate expenses
| EUR 1,000 | 01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
|---|---|---|
| Bank charges and commitment fees | 139 | 91 |
| Board member fees | 116 | 119 |
| D&O insurance fees | 18 | 15 |
| Marketing and public relations fees | 49 | 39 |
| Professional fees (audit, legal and tax) | 61 | 65 |
| Other expenses | 28 | 30 |
| Total corporate expenses | 411 | 359 |
7. Payables and accrued expenses
| EUR 1,000 | 30.09.21 | 31.03.21 |
|---|---|---|
| Payables to third parties | 269 | 32 |
| Accrued expenses | 51 | 61 |
| Total payables and accrued expenses | 320 | 93 |
8. Unfunded commitments
As of September 30, 2021, the Group's unfunded commitments amounted to EUR 116.2 million (March 31, 2021: EUR 80.8 million) (refer to Note 10).
9. Financial liabilities at amortised cost
Interest bearing borrowings and credit facility/pledged assets
Effective on June 1, 2017, the Company (the borrower) increased the maximum loan amount with Private Equity Fund Finance Ltd (a subsidiary, the lender) to CHF 70.0 million at the existing interest rate of 1 month LIBOR plus 200 basis points. As LIBOR will be replaced by alternative reference rates for the respective currencies from January 1, 2022 onwards, the interest calculation methodology will be amended accordingly. A material impact for the Company is not expected. The lender may extend further loans to the borrower if and as required by the borrower to carry on its business by entering into a letter agreement which shall be governed by the same provisions as set forth in the existing loan agreement. The lender may not request the repayment of any amount outstanding without giving at least 12 months notice. There is no contractually agreed expiry date. The total amount of interest bearing borrowings as of September 30, 2021 stood at EUR 60.9 million (March 31, 2021: EUR 54.6 million).
On December 21, 2018, the Company signed an amended agreement with Credit Suisse (Schweiz) AG for a EUR 20.0 million revolving credit facility, which was subsequently increased to EUR 30.0 million on September 16, 2019. This agreement will come up for renewal effective December 31, 2021. This facility allows the Company to bridge timing gaps between outflows and inflows, cover short-term liquidity squeezes and manage and hedge market risks. The credit facility, if and when drawn, is secured by the Company's ownership interests in Private Equity Fund Finance Ltd and Private Equity Direct Finance Ltd The applicable interest rate on any amounts outstanding under the facility is LIBOR for the requested currency term (floored at 0%) plus 185 basis points. The Company is obliged to pay a quarterly commitment fee of 22.5 basis points on the undrawn amount.
As of September 30, 2021, the credit facility drawn was EUR 6.6 million (March 31, 2021: EUR 5.9 million) and is presented as short-term bank borrowing in the balance sheet. During the first half of the financial year 2021/2022, interest expenses of EUR 18k were incurred (September 30, 2020: EUR 114k). Commitment fees amounted to EUR 128k for the first half of the business year 2021/2022 (September 30, 2020: EUR 80k) and are included in the statement of comprehensive income.
10. Investments in non-consolidated subsidiaries at fair value through profit or loss and financial assets at fair value through profit or loss
10.1 Investments in non-consolidated subsidiaries at fair value through profit or loss
| Percentage of capital held |
Original currency |
Nominal value 1,000 |
Book value 30.09.21 EUR 1,000 |
Book value 31.03.21 EUR 1,000 |
|
|---|---|---|---|---|---|
| Investments in non-consolidated subsidiaries at fair value through profit or loss | |||||
| Private Equity Fund Finance Ltd, Cayman Islands (Investment company) | 100% | CHF | 13,885 | 371,503 | 325,369 |
| Private Equity Direct Finance Ltd, Cayman Islands (Investment company) | 100% | CHF | 200,000 | 52,433 | 41,678 |
| Total | 423,936 | 367,047 |
| Private Equity Fund Finance Ltd | Private Equity Direct Finance Ltd | Total | |
|---|---|---|---|
| Fund investments | 286,792 | — | 286,792 |
| Direct investments | 15,414 | 60,625 | 76,039 |
| Other balance sheet items | 69,297 | (8,192) | 61,105 |
| Book value 30.09.21 | 371,503 | 52,433 | 423,936 |
| Private Equity Fund Finance Ltd | Private Equity Direct Finance Ltd | Total | |
|---|---|---|---|
| Fund investments | 254,052 | — | 254,052 |
| Direct investments | 17,800 | 43,420 | 61,220 |
| Other balance sheet items | 53,517 | (1,742) | 51,775 |
| Book value 31.03.21 | 325,369 | 41,678 | 367,047 |
The functional currency of the non-consolidated subsidiaries at fair value through profit or loss is EUR.
Investments held by the non-consolidated subsidiaries
| Commitments | Book values | ||||||
|---|---|---|---|---|---|---|---|
| Vintage | Original fund currency |
Original amount FC 1,000 |
Paid in 30.09.21 FC 1,000 |
Unfunded commitment 30.09.21 EUR 1,000 |
Fair value 31.03.21 EUR 1,000 |
Fair value 30.09.21 EUR 1,000 |
|
| Buyout Funds | |||||||
| ABRY Heritage Partners 3 | 2016 | USD | 5,600 | 4,796 | 694 | 3,112 | 2,922 |
| ABRY Heritage Partners II | 2021 | USD | 10,000 | — | 8,630 | — | — |
| ABRY Partners IX 3 | 2019 | USD | 8,571 | 5,908 | 2,298 | 3,988 | 5,025 |
| ABRY Partners VI 3 | 2008 | USD | 7,500 | 7,498 | 2 | 115 | 132 |
| ABRY Partners VII 3 | 2011 | USD | 7,500 | 8,093 | — | 2,136 | 2,165 |
| ABRY Partners VIII 3 | 2014 | USD | 9,375 | 10,077 | — | 5,294 | 2,264 |
| ALPHA CEE II 2 | 2006 | EUR | 15,000 | 14,163 | 837 | 4,528 | 3,938 |
| Avista Capital Partners II 3 | 2008 | USD | 10,000 | 13,122 | — | 704 | 710 |
| Avista Capital Partners III 3 | 2011 | USD | 10,000 | 11,459 | — | 73 | 72 |
| Avista Capital Partners IV 3 | 2017 | USD | 5,000 | 5,396 | — | 6,510 | 2,469 |
| Bi-Invest Endowment Fund | 2014 | EUR | 5,000 | 5,000 | — | 8,284 | 9,853 |
| Bridgepoint Europe IV 3 | 2008 | EUR | 10,000 | 10,451 | — | 1,994 | 2,197 |
| Capvis Equity III | 2008 | EUR | 10,000 | 10,857 | 545 | 2,684 | — |
| Cinven VII | 2019 | EUR | 5,000 | 1,198 | 3,802 | 550 | 1,395 |
| CIVC VI | 2021 | USD | 5,000 | 285 | 4,068 | — | 246 |
| Clayton, Dubilier and Rice Fund VI 1 | 1998 | USD | 35,000 | 9,661 | — | 4 | 3 |
| Eagletree Partners III 3 | 2012 | USD | 10,000 | 10,761 | — | 3,899 | 4,011 |
| Eagletree Partners IV 3 | 2015 | USD | 10,000 | 10,561 | — | 14,232 | 11,889 |
| Gyrus Capital Co-Investment Fund | 2020 | EUR | 3,000 | 1,000 | 2,000 | — | 997 |
| Gyrus Capital Principal Fund | 2020 | EUR | 1,500 | 1,013 | 487 | — | 1,158 |
| Industri Kapital 2007 Fund 3 | 2007 | EUR | 10,000 | 10,427 | — | 14 | 13 |
| Insight Venture Partners XII Buyout Annex | 2021 | USD | 2,000 | 500 | 1,294 | — | 431 |
| Investindustrial IV 3 | 2008 | EUR | 10,000 | 10,919 | — | 3,401 | 3,241 |
| Investindustrial V 3 | 2012 | EUR | 5,000 | 5,840 | — | 3,732 | 4,603 |
| Investindustrial VI 3 | 2016 | EUR | 5,000 | 4,599 | 401 | 5,434 | 6,466 |
| Investindustrial VII 3 | 2019 | EUR | 5,000 | 1,367 | 3,649 | 303 | 1,277 |
| Mid Europa Fund IV 3 | 2014 | EUR | 10,000 | 10,411 | — | 13,033 | 14,177 |
| Mid Europa Fund V | 2018 | EUR | 5,000 | 2,194 | 2,806 | 1,352 | 2,345 |
| Pollen Street Capital III | 2016 | GBP | 9,000 | 9,294 | — | 11,223 | 13,580 |
| Pollen Street Capital IV | 2020 | GBP | 9,000 | — | 10,487 | — | — |
| Procuritas Capital Investors VI 3 | 2016 | EUR | 10,000 | 5,897 | 4,103 | 3,808 | 5,780 |
| TA Associates XIII | 2019 | USD | 5,000 | 4,119 | 837 | 2,915 | 3,922 |
| TA Associates XIV | 2021 | USD | 7,000 | — | 6,041 | — | — |
| Warburg Pincus China-Southeast Asia II | 2019 | USD | 5,000 | 1,233 | 3,251 | 714 | 1,336 |
| Warburg Pincus Private Equity X | 2007 | USD | 15,000 | 15,263 | 14 | 1,089 | 317 |
| Warburg Pincus Private Equity XII | 2015 | USD | 6,000 | 5,919 | 70 | 6,000 | 7,272 |
| Total Buyout Funds | 56,315 | 111,125 | 116,205 |
Minor differences in totals are due to rounding.
1 Fund investments included in the former Earn-out portfolio. These funds are reaching the end of their life and are fully or almost fully paid in. A few earn-out funds could re-call a portion of previous distributions for follow-on investments. Future fund expenses, if any, are likely to be deducted from future distributions. Therefore, no unfunded commitment is shown for the former earn-out funds.
2 Funds managed by ALPHA Associates (Cayman) LP. These funds are excluded from the NAV for the purpose of calculating the management fee.
3 Along with the unfunded commitments, distributions in the total amount of EUR 15.9 million (whereof Eagletree Partners IV accounts for EUR 2.0 million, Procuritas Capital Investors VI accounts for EUR 1.3 million and Eagletree Partners III accounts for EUR 1.2 million) are recallable from these funds as of September 30, 2021. As the investment period of most of these funds has already expired, recallable distributions can in general only be recycled for follow-on investments and are therefore not expected to be drawn in full.
4 Remaining commitment was reduced by the fund manager.
5 As of September 30, 2021, the EMP portfolio (Emerging Managers Program) consists of ten underlying venture capital funds with vintage years 2018, 2019, 2020 and 2021. Six of these funds are denominated in USD (total original amount: USD 6.5 million; total amount paid-in as of September 30, 2021: USD 4.4 million), and the other four are denominated in GBP (total original amount: GBP 2.6 million; total amount paid-in as of September 30, 2021: GBP 1.9 million).
6 As of September 30, 2021, the co-investments group consists of four underlying co-investments. Three of these co-investments are denominated in USD (total original amount: USD 7.4 million) and the other one in EUR (total original amount: EUR 4.4 million). For this group of co-investments the Company is subject to strict confidentiality requirements and therefore not allowed to disclose any itemised information.
Investments held by the non-consolidated subsidiaries (continued)
| Commitments | Book values | ||||||
|---|---|---|---|---|---|---|---|
| Vintage | Original fund currency |
Original amount FC 1,000 |
Paid in 30.09.21 FC 1,000 |
Unfunded commitment 30.09.21 EUR 1,000 |
Fair value 31.03.21 EUR 1,000 |
Fair value 30.09.21 EUR 1,000 |
|
| Venture Funds | |||||||
| Boulder Ventures IV | 2001 | USD | 11,250 | 11,516 | — | 1,344 | 3,009 |
| CDC Innovation 2000 | 2000 | EUR | 10,002 | 9,676 | 326 | 354 | 417 |
| Clarus Lifesciences III | 2013 | USD | 7,500 | 7,163 | 291 | 6,828 | 3,260 |
| Clarus IV 3 | 2017 | USD | 7,500 | 5,671 | 1,586 | 4,226 | 5,891 |
| Emerging Managers Program 3, 5 | 2018-21 | Various | Various | Various | 2,663 | 4,909 | 8,830 |
| Evolution Technology 3 | 2016 | USD | 5,000 | 5,172 | — | 8,058 | 7,916 |
| Evolution Technology II | 2019 | USD | 3,000 | 1,772 | 1,060 | — | 1,529 |
| Growth Fund I | 2011 | EUR | 5,000 | 5,627 | — | 4,759 | 3,999 |
| Growth Fund II | 2015 | EUR | 5,000 | 5,638 | — | 19,697 | 22,818 |
| Growth Fund III | 2018 | USD | 4,500 | 4,437 | 54 | 4,192 | 6,706 |
| Growth Fund IV | 2020 | USD | 4,500 | 3,773 | 627 | 1,481 | 3,307 |
| Growth Fund V | 2021 | USD | 6,000 | — | 5,178 | — | — |
| Highland Europe I 3 | 2012 | EUR | 5,000 | 6,229 | — | 7,429 | 7,544 |
| Highland Europe II 3 | 2015 | EUR | 5,000 | 5,345 | 149 | 8,278 | 12,134 |
| Highland Europe III 3 | 2018 | EUR | 5,000 | 4,177 | 843 | 6,262 | 6,555 |
| Highland Europe IV | 2020 | EUR | 5,000 | 975 | 4,025 | (16) | 914 |
| Insight Venture Partners XII | 2021 | USD | 5,000 | 1,250 | 3,236 | — | 1,069 |
| Institutional Venture Partners XII | 2007 | USD | 5,000 | 5,000 | — | 141 | 142 |
| Institutional Venture Partners XIII | 2010 | USD | 5,000 | 5,000 | — | 2,399 | 2,931 |
| Kennet III 3 | 2007 | EUR | 5,000 | 5,669 | — | 802 | 722 |
| L1D Blockchain Venture | 2021 | USD | 600 | 270 | 285 | — | 545 |
| Life Sciences Fund | 2019 | EUR | 4,000 | 702 | 3,298 | 303 | 456 |
| Pelion IV | 2007 | USD | 1,693 | 1,693 | — | 92 | 74 |
| Pelion V | 2012 | USD | 1,039 | 1,039 | — | 277 | 345 |
| Pelion VI | 2015 | USD | 5,000 | 5,000 | — | 8,406 | 10,592 |
| TAT Investments I | 1997 | USD | 24,000 | 24,289 | — | 64 | 75 |
| Venture Fund I | 2021 | USD | 1,500 | — | 1,294 | — | — |
| Total Venture Funds | 24,915 | 90,284 | 111,779 |
For footnotes see bottom of page 17.
Minor differences in totals are due to rounding.
Investments held by the non-consolidated subsidiaries (continued)
| Commitments | Book values | ||||||
|---|---|---|---|---|---|---|---|
| Vintage | Original fund currency |
Original amount FC 1,000 |
Paid in 30.09.21 FC 1,000 |
Unfunded commitment 30.09.21 EUR 1,000 |
Fair value 31.03.21 EUR 1,000 |
Fair value 30.09.21 EUR 1,000 |
|
| Special Situation Funds | |||||||
| ABRY Advanced Securities Fund 4 | 2008 | USD | 15,000 | 7,277 | 412 | 158 | 106 |
| ABRY Advanced Securities Fund III | 2014 | USD | 8,000 | 9,933 | — | 6,207 | 6,788 |
| ABRY Advanced Securities Fund IV 3 | 2018 | USD | 10,000 | 5,312 | 4,046 | 4,160 | 4,594 |
| ABRY Senior Equity IV 3 | 2013 | USD | 5,000 | 5,174 | — | 1,260 | 940 |
| ABRY Senior Equity V 3 | 2016 | USD | 5,500 | 5,224 | 238 | 3,814 | 4,672 |
| ABRY Senior Equity VI | 2021 | USD | 6,000 | — | 5,178 | — | — |
| ALPHA CEE Opportunity IV 2 | 2016 | EUR | 10,000 | 9,547 | 1,026 | 22,683 | 25,115 |
| ALPHA CEE Opportunity V 2 | 2021 | EUR | 5,000 | 1,285 | 3,715 | 780 | 1,267 |
| ALPHA Russia & CIS Secondary 2 | 2010 | USD | 15,000 | 13,890 | 958 | 7,009 | 6,120 |
| DB Secondary Opportunities Fund A 4 | 2007 | USD | 5,376 | 4,327 | 453 | — | — |
| DB Secondary Opportunities Fund C | 2007 | USD | 9,288 | 6,957 | 2,049 | — | — |
| HIG Middle Market LBO III | 2019 | USD | 5,000 | 680 | 3,728 | 276 | 561 |
| OCM European Principal Opportunities Fund II | 2007 | EUR | 5,000 | 4,995 | 5 | 66 | 8 |
| OCM Opportunities Fund VII | 2007 | USD | 5,000 | 5,000 | — | 34 | 31 |
| OCM Opportunities Fund VIIb | 2008 | USD | 5,000 | 4,500 | 216 | 8 | 4 |
| Sycamore II 3 | 2014 | USD | 10,000 | 8,873 | 973 | 3,537 | 4,520 |
| Sycamore III | 2018 | USD | 10,000 | 4,549 | 4,704 | 2,513 | 3,946 |
| WL Ross Recovery Fund IV 3 | 2007 | USD | 10,000 | 9,056 | 814 | 138 | 136 |
| Total Special Situation Funds | 28,515 | 52,643 | 58,807 | ||||
| Total Fund Investments | 109,745 | 254,052 | 286,792 |
For footnotes see bottom of page 17.
Minor differences in totals are due to rounding.
| Commitments | Book values | |||||
|---|---|---|---|---|---|---|
| Vintage | Original amount FC 1,000 |
Unfunded commitment 30.09.21 EUR 1,000 |
Fair value 31.03.21 EUR 1,000 |
Fair value 30.09.21 EUR 1,000 |
||
| Direct investments | ||||||
| Acino Holding AG | USD | 5,455 | — | 5,547 | 7,363 | |
| Applied Spectral Imaging | USD | 4,461 | — | 1,886 | 1,910 | |
| Aston Martin | EUR | 4,737 | — | 2,304 | 2,192 | |
| Cloudflare | USD | 2,006 | — | — | — | |
| Dupont Sustainable Solutions | USD | 6,513 | 1,967 | 8,052 | 10,728 | |
| Earnix | USD | 201 | — | 17,094 | 15,155 | |
| Enanta Pharmaceuticals | USD | 7,279 | — | 450 | — | |
| International Design Group (formerly Flos) | EUR | 4,172 | — | 3,009 | 4,399 | |
| Morgan Motor | EUR | 1,861 | — | 2,329 | 2,723 | |
| Natural Capital Partners (formerly Carbon Neutral) | USD | 353 | — | — | — | |
| Neurotech | USD | 2,203 | — | 465 | — | |
| Ozon | USD | 1,410 | — | 6,973 | 5,580 | |
| Renaissance Learning | USD | 6,625 | — | 7,705 | 11,573 | |
| Shawbrook | GBP | 4,000 | — | 5,406 | 8,147 | |
| Various co-investments 6 | Various | Various | 4,447 | — | 6,271 | |
| Total Direct investments | 6,414 | 61,220 | 76,039 |
For footnotes see bottom of page 17.
Minor differences in totals are due to rounding.
10.2 Movements in investments held by the non-consolidated subsidiaries
| Returns | |||||||
|---|---|---|---|---|---|---|---|
| Book values | 01.04.21-30.09.21 | ||||||
| Fair value | Capital | Return | Change in unrealised |
Fair value | Total distri |
Real. gains/ |
|
| 01.04.21 EUR 1,000 |
calls EUR 1,000 |
of capital EUR 1,000 |
gains/(losses) EUR 1,000 |
30.09.21 EUR 1,000 |
butions EUR 1,000 |
(losses) EUR 1,000 |
|
| Fund Investments 1 | |||||||
| Buyout Funds | 111,125 | 9,089 | 11,797 | 7,788 | 116,205 | 18,935 | 7,138 |
| Venture Funds | 90,284 | 9,637 | 4,811 | 16,669 | 111,779 | 21,038 | 16,227 |
| Special Situation Funds | 52,643 | 2,542 | 2,051 | 5,673 | 58,807 | 3,829 | 1,777 |
| Total Funds | 254,052 | 21,269 | 18,659 | 30,131 | 286,792 | 43,802 | 25,142 |
| Direct Investments 2 | 61,220 | 7,758 | 992 | 8,053 | 76,039 | 2,794 | 1,802 |
| Total Investments held by | |||||||
| the non-consolidated subsidiaries | 315,272 3 | 29,027 | 19,651 | 38,184 | 362,831 | 46,596 | 26,944 |
Minor differences in totals are due to rounding.
1 Fund Investments were held by Private Equity Fund Finance (also refer to Note 10.1).
2 Direct Investments were held by Private Equity Direct Finance and Private Equity Fund Finance (also refer to Note 10.1).
3 In addition Private Equity Fund Finance held a quoted security, which was received as an in-kind distribution. As of March 31, 2021 the market value was EUR 191k.
10.3 Financial assets at fair value through profit or loss
| Commitments | Book values | Returns 01.04.21-30.09.21 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Original currency |
Original amount FC 1,000 |
Unfunded commit ment 30.09.21 EUR 1,000 |
Fair value 01.04.21 EUR 1,000 |
Capital calls EUR 1,000 |
Return of capital EUR 1,000 |
Change in unrealised gains/ (losses) EUR 1,000 |
Fair value 30.09.21 EUR 1,000 |
Total distri butions EUR 1,000 |
Real. gains/ (losses) EUR 1,000 |
|
| Actano Holding AG (Equity) | CHF | 8,450 | — | 1,087 | — | — | — | 1,087 | — | — |
| Minicap Technology Investments | CHF | 10,967 | — | — | — | — | — | — | — | — |
| Strategic European Technologies N.V. | EUR | 18,151 | — | 198 | — | — | — | 198 | — | — |
| Total financial assets at fair value through profit or loss |
— | 1,285 | — | — | — | 1,285 | — | — |
Minor differences in totals are due to rounding.
11. Net gains/(losses) from investments in non-consolidated subsidiaries at fair value through profit or loss and from financial assets at fair value through profit or loss
| Non-consolidated subsidiaries | ||
|---|---|---|
| EUR 1,000 | 01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
| Change in unrealised gains/(losses) on Private Equity Fund Finance Ltd | 46,134 | (8,105) |
| Change in unrealised gains/(losses) on Private Equity Direct Finance Ltd | 10,755 | (2,783) |
| Total net gains/(losses) from investments in non-consolidated subsidiaries at fair value through profit or loss | 56,889 | (10,888) |
| Financial assets | ||
| EUR 1,000 | 01.04.21- 30.09.21 |
01.04.20- 30.09.20 |
| Change in unrealised gains/(losses) from financial assets at fair value through profit or loss | — | (543) |
| Total net gains/(losses) from financial assets at fair value through profit or loss | — | (543) |
"Net gains/(losses) from investments in non-consolidated subsidiaries at fair value through profit or loss" includes all realised and unrealised fair value changes, dividends and interest income from investments held by the non-consolidated subsidiaries and foreign exchange differences.
"Net gains/(losses) from financial assets at fair value through profit or loss" includes all realised and unrealised fair value changes, dividends and interest income from investments held directly by the Company and foreign exchange differences.
12. Segment information
Due to the nature of the business (all private equity investments), the Board of Directors has decided that there are no separate reporting segments.
13. Disclosures about fair value of financial instruments
The table below analyses recurring fair value measurements for the Company's financial instruments. These fair value measurements are categorised into different levels in the fair value hierarchy based on the inputs to valuation techniques used. The different levels are defined as follows:
- Level I inputs are quoted prices (unadjusted) in active markets for identical instruments that the Group can access at the measurement date
- Level II inputs are inputs other than quoted prices included within Level I that are observable for the instrument, either directly or indirectly
- Level III inputs are unobservable inputs for the instrument
The level in the fair value hierarchy within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level III measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgment, considering factors specific to the instrument. The determination of what constitutes "observable" requires significant judgment by the Company. The Company considers observable data to be market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.
The following table analyses the Company's investments measured at fair value as of September 30, 2021 and March 31, 2021 on a look-through basis by the level in the fair value hierarchy into which the fair value measurement is categorised 1 :
| As of September 30, 2021 | ||||
|---|---|---|---|---|
| EUR 1,000 | Level I | Level II | Level III | Total |
| Investments in non-consolidated subsidiaries (look-through) | ||||
| Fund investments | — | — | 286,792 | 286,792 |
| Direct investments | 2,192 | — | 73,847 | 76,039 |
| Total investments in non-consolidated subsidiaries (look-through) | 2,192 | — | 360,639 | 362,831 |
| Financial assets at fair value through profit or loss | ||||
| Fund investments | — | — | 198 | 198 |
| Direct investments | — | — | 1,087 | 1,087 |
| Loans | — | — | — | — |
| Total financial assets measured at fair value through profit or loss | — | — | 1,285 | 1,285 |
| As of March 31, 2021 | ||||
| EUR 1,000 | Level I | Level II | Level III | Total |
| Investments in non-consolidated subsidiaries (look-through) | ||||
| Fund investments | — | — | 254,052 | 254,052 |
| Direct investments | 2,754 | — | 58,466 | 61,220 |
| Total investments in non-consolidated subsidiaries (look-through) | 2,754 | — | 312,518 | 315,272 |
| Financial assets at fair value through profit or loss | ||||
| Fund investments | — | — | 198 | 198 |
| Direct investments | — | — | 1,087 | 1,087 |
| Total financial assets measured at fair value through profit or loss | — | — | 1,285 | 1,285 |
1 The Company has not disclosed the fair values for financial instruments measured at amortised cost. For short-term financial instruments such as cash and cash equivalent, receivables, payables and accrued expenses, the carrying amount is generally considered a reasonable estimate of fair value. The fair value for long-term financial liabilities such as as interest-bearing borrowings, estimated by discounting contractual cash flows using current market interest rates is equivalent to the carrying amount.
The Company recognises transfers between levels of the fair value hierarchy as of the end of the reporting period during which the transfer has occurred. There were no transfers between the levels during the six months ended September 30, 2021.
The changes in investments measured at fair value for which the Company has used Level III inputs to determine fair value as of September 30, 2021 and March 31, 2021 are as follows:
| As of September 30, 2021 EUR 1,000 |
Investments in non consolidated subsidiaries at fair value through profit or loss |
Financial assets at fair value through profit or loss |
Total |
|---|---|---|---|
| Fair value of Level III investments at the beginning of the period | 312,518 | 1,285 | 313,803 |
| Total capital calls from Level III investments | 29,026 | — | 29,026 |
| Total distributions from Level III investments | (46,131) | — | (46,131) |
| Total gains or losses: | |||
| realised in profit or loss | 26,517 | — | 26,517 |
| unrealised in profit or loss 1 | 38,709 | — | 38,709 |
| Fair value of Level III investments at the end of the period | 360,639 | 1,285 | 361,924 |
| As of March 31, 2021 EUR 1,000 |
Investments in non consolidated subsidiaries at fair value through profit or loss |
Financial assets at fair value through profit or loss |
Total |
|---|---|---|---|
| Fair value of Level III investments at the beginning of the period | 241,065 | 2,371 | 243,436 |
| Total capital calls from Level III investments | 31,847 | — | 31,847 |
| Total distributions from Level III investments | (57,063) | — | (57,063) |
| Total gains or losses: | |||
| realised in profit or loss | 33,469 | — | 33,469 |
| unrealised in profit or loss 1 | 63,200 | (1,086) | 62,114 |
| Fair value of Level III investments at the end of the period | 312,518 | 1,285 | 313,803 |
1 Unrealised profit or loss refers to instruments held at the reporting date.
For Level III fund and direct investments, the sensitivity analysis below (as of September 30, 2021 and March 31, 2021) represents the potential absolute change in fair value for each category. The fair values of such investments are valued by using an unobservable input factor and are directly affected by a change in that factor.
The Company utilises a methodology that uses reported NAV as the key input for fund investments. Thus, the main unobservable input factor would be reported NAV itself. For direct investments, the Company used mainly the following factors relevant to the fair value: a) Reported fair value, b) EBITDA multiples or other earnings metric as appropriate and c) Recent financing transactions adjusted for possible changes between transaction date and reporting date.
The COVID-19 pandemic has changed the global economic outlook for the foreseeable future. Given the uncertainty of the outcome of current events and the observable financial market volatility since March 2020, the percentage used in the sensitivity analysis for the negative change of the unobservable input factor remains doubled at 10% as of September 30, 2021. This percentage currently represents the Board of Directors' best estimate of a reasonable possible shift in the inputs. Hence, should the significant unobservable input increase by 5% or decrease by 10%, the value of each category of investments would follow respectively by the absolute positive or negative amount as shown in the table below.
No interrelationships between unobservable inputs used in the Company's valuation of its Level 3 funds and direct investments have been identified.
The category "Direct investments" in the table below may include certain investments using the valuation technique "Reported fair value". The fair value of such direct investments is based on a reported fair value by the lead investor. Hence, we use the reported fair value rather than a direct investment valuation.
A sensitivity analysis has not been performed for direct investments that have been acquired within the last 9 months of the reporting period and where the acquisition cost was deemed to be the most appropriate fair value in accordance with IFRS 13.
| Fair value | Sensitivity | ||||
|---|---|---|---|---|---|
| Level III investment | 30.09.21 EUR 1,000 |
Valuation technique | Unobservable input | +5% | -10% |
| Fund investments | |||||
| 286,990 | Adjusted reported net asset value |
Marketability discount | 14,350 | (28,699) | |
| Direct investments | |||||
| 17,065 | Market comparable companies |
Enterprise value to EBITDA multiple |
853 | (1,706) | |
| 56,782 | Reported fair value | Reported fair value | 2,839 | (5,678) | |
| 1,087 | Recent financing/ transaction |
Recent transaction price |
n/a | n/a | |
| - | Other | Earnout | n/a | n/a |
n/a = not meaningful
| Fair value | Sensitivity | ||||
|---|---|---|---|---|---|
| Level III investment | 31.03.21 EUR 1,000 |
Valuation technique | Unobservable input | +5% | -10% |
| Fund investments | |||||
| 254,250 | Adjusted reported net asset value |
Marketability discount | 12,713 | (25,425) | |
| Direct investments | |||||
| 18,980 | Market comparable companies |
Enterprise value to EBITDA multiple |
949 | (1,898) | |
| 39,021 | Reported fair value | Reported fair value | 1,951 | (3,902) | |
| 1,087 | Recent financing/ transaction |
Recent transaction price |
n/a | n/a | |
| 465 | Other | Earnout | n/a | n/a |
n/a = not meaningful
14. Subsequent events
There were no subsequent events.
Information for Investors
The registered shares of Private Equity Holding AG are traded on SIX Swiss Exchange since January 18, 1999.
| Stock exchange listing | |
|---|---|
| Telekurs ticker symbol | PEHN |
| Swiss security no. | 608 992 |
| ISIN code | CH 000 608 9921 |
| German security no. | 906 781 |
Corporate calendar
| April 11, 2022 | NAV as of March 31, 2022 |
|---|---|
| May 10, 2022 | Annual Report 2021/2022 |
| June 2, 2022 | Annual General Meeting |
NAV Publication as of the end of every month on www.peh.ch
| Capital calls | Amount of capital called from the Group by a private equity fund. Each transaction is translated into EUR by using the foreign exchange rate as of the transaction date. |
|---|---|
| Capital contributed (invested) | Amount of capital contributed (invested) by the Group to direct or indirect investments since inception. Each transaction is translated into EUR by using the foreign exchange rate as of the transaction date. |
| Capital gain/(loss) | Difference between total distribution and the cost component of distribution of a specific investment. |
| Change in unrealised gain/ (loss) |
Temporary increase or decrease in value of a fund or direct investment. Equal to the difference between the fair value of an investment and the net acquisition cost. |
| Commitment | Amount that the Group has committed to make available to a private equity fund or direct investment. In accordance with IFRS, this amount is not recorded in the balance sheet. The translation into EUR is made by using the foreign exchange rate as of the relevant reporting date. |
| Cost component of distribution (return of capital) |
Portion of distribution which reflects the contributed capital. |
| Distribution | Amount of net proceeds (including cost component, capital gains and interest/ dividends) received by the Group. Each transaction is translated into EUR by using the foreign exchange rate as of the transaction date. |
| Fair value (FV) | The price at which an investment would change hands between a willing buyer and a willing seller, neither being under a compulsion to buy or sell and both having a reasonable knowledge of relevant facts. Fair value of a private equity fund, i.e. fair value of assets minus liabilities. The translation into EUR is made by using the foreign exchange rate as of the relevant reporting date. |
| NAV | Net asset value |
| Net acquisition cost (NAC) | Capital contributed minus cost component of distributions. |
| Realised gain/(loss) | Difference between total distribution and the cost component of distribution of a specific investment. |
| Unfunded commitment | Amount that the Group has not yet contributed to a private equity fund. Difference between original commitment and contributed capital. |
| Vintage year | Year in which a private equity fund has made its first capital call for investment purposes. In general, this coincides with the first year of a private equity fund's term. |
Glossary of Terms
Private Equity Holding AG Gotthardstrasse 28 CH-6302 Zug Phone +41 41 726 79 80 Fax +41 41 726 79 81
www.peh.ch [email protected]